List of Excipients in Branded Drug GADAVIST

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	GADAVIST	gadobutrol	50419-325	HYDROCHLORIC ACID
Bayer HealthCare Pharmaceuticals Inc	GADAVIST	gadobutrol	50419-325	TROMETHAMINE
Bayer HealthCare Pharmaceuticals Inc	GADAVIST	gadobutrol	50419-325	WATER

Gadavist Excipient Strategy, Formulation Patents, Generic Risk, and Commercial Opportunities

Last updated: October 20, 2026

Gadavist is Bayer’s gadobutrol-based, macrocyclic gadolinium contrast agent for magnetic resonance imaging. Its U.S. formulation is deliberately simple: 1 mmol/mL gadobutrol in water for injection, without a conventional preservative or complex excipient system. The commercial opportunity therefore lies less in replacing excipients and more in improving container closure, ready-to-use delivery, dose logistics, stability, manufacturing efficiency, and differentiated presentations. [1]

What is Gadavist and how is it formulated?

Gadavist contains gadobutrol at a concentration of 604.72 mg/mL, equivalent to 1 mmol/mL. The labeled inactive ingredient is water for injection. The product is supplied as a sterile, nonpyrogenic solution for intravenous administration. The labeled pH range is approximately 6.6 to 8.0, and the product has high osmolality relative to plasma. [1]

Attribute	Gadavist profile
Brand	Gadavist
Active ingredient	Gadobutrol
Drug class	Macrocyclic gadolinium-based contrast agent
U.S. sponsor	Bayer HealthCare Pharmaceuticals Inc.
FDA application	NDA 201277
Strength	1 mmol/mL
Gadobutrol concentration	604.72 mg/mL
Primary excipient	Water for injection
Preservative	None identified in the U.S. label
Route	Intravenous
Dosage forms	Single-dose injection presentations
Primary uses	CNS, breast, cardiac and vascular MRI indications, depending on approved labeling
FDA approval	2011 initial U.S. approval

The formulation strategy is based on a highly water-soluble gadobutrol complex that does not require surfactants, cosolvents, buffers or antimicrobial preservatives in the marketed U.S. product. That reduces excipient-related toxicology, compatibility and regulatory complexity.

Why is Gadavist’s minimal excipient system commercially important?

A minimal formulation provides several advantages:

• Fewer raw materials and fewer supplier dependencies.
• Lower risk of excipient-related impurities and extractables.
• Simpler compendial testing.
• Reduced risk of hypersensitivity attributable to formulation components.
• Easier global adaptation where excipient restrictions differ.
• A clearer regulatory pathway for a generic or 505(b)(2) injectable product.

The tradeoff is that the manufacturer has fewer formulation levers. Product differentiation must come from packaging, device integration, manufacturing control, supply reliability and workflow economics.

What excipients and materials are used in Gadavist presentations?

The formulation itself is primarily water for injection and gadobutrol. The commercial product also depends on packaging materials that are not generally listed as formulation excipients.

Primary formulation components

Component	Strategic function	Commercial implication
Gadobutrol	Macrocyclic gadolinium chelate and active pharmaceutical ingredient	Requires high-purity, tightly controlled API supply
Water for injection	Solvent and vehicle	Requires sterile water generation, validated storage and microbial control
No conventional preservative	Supports single-dose sterile use	Increases dependence on aseptic processing and container integrity
No surfactant or cosolvent identified	Supports a relatively simple solution system	Limits opportunities for excipient substitution

The FDA label does not identify a conventional buffer system, surfactant or tonicity agent as an inactive ingredient. That matters for competitive development: a proposed generic should not introduce an unnecessary excipient unless it solves a documented problem such as pH control, adsorption, precipitation, syringe compatibility or container interaction.

Packaging materials as an excipient-adjacent opportunity

The most commercially relevant materials may sit outside the formulation:

• Type I glass vials.
• Rubber stoppers.
• Aluminum seals.
• Syringe barrels and plungers.
• Silicone or alternative lubrication systems.
• Labels and secondary packaging.
• Automated injector-compatible containers.
• Low-extractables elastomer components.

For a high-concentration injectable, container closure performance is a central development issue. The relevant risks include tungsten or glass particles, elastomer extractables, stopper coring, silicone migration, adsorption, leachables and loss of container closure integrity.

What formulation patents protect Gadavist?

Gadavist’s commercial protection historically has been associated primarily with gadobutrol composition, production, medical use and formulation-related intellectual property rather than a complex excipient platform.

A current patent-by-patent conclusion requires review of the live USPTO, WIPO, FDA Orange Book and court records. The public FDA label does not identify an excipient-specific patent protection strategy. The practical competitive question is therefore whether any enforceable claims remain that cover:

1. Gadobutrol itself or a specific salt, stereochemical or chelate form.
2. A high-concentration injectable gadobutrol solution.
3. Specific medical imaging uses.
4. Manufacturing or purification processes.
5. Container or delivery configurations.
6. Stability, impurity or sterilization controls.

What patent claims would matter most to a competitor?

Claim category	Relevance to generic or follow-on developer
Composition claims	Potentially high, if still enforceable
Solution formulation claims	Relevant if concentration, pH or excipient ranges are claimed
Method-of-use claims	Relevant to indication-specific labeling and carve-outs
Manufacturing claims	Relevant if the process is difficult to design around
Container claims	Relevant to prefilled syringes, injector systems and specialty presentations
Stability claims	Relevant if they cover a commercially necessary shelf-life profile

A simple water-for-injection formulation generally creates less formulation-patent density than a product containing specialized buffers, stabilizers or delivery technologies. The main barrier may instead be the difficulty of producing high-purity gadobutrol and demonstrating injectable-product equivalence.

When does Gadavist lose exclusivity and what is the generic entry risk?

Gadavist received U.S. approval in 2011. The statutory five-year new chemical entity period would have delayed an ANDA submission until 2016, subject to the specific regulatory history and any applicable exclusivity extensions. The exact date of commercial generic entry depends on remaining patents, certifications, litigation, settlement terms and FDA approval timing.

Gadavist is a small-molecule drug, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. A competing product would generally pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence, or a 505(b)(2) pathway if it relies on some different formulation, presentation or clinical bridge.

Generic entry scenarios

Scenario	Likely pathway	Market impact
Same gadobutrol concentration and injectable presentation	ANDA	Highest direct substitution potential
Different container or delivery system	ANDA or 505(b)(2)	Potential workflow differentiation
New excipient or materially changed formulation	Usually 505(b)(2) risk increases	More clinical and CMC burden
New indication or modified administration method	505(b)(2) or supplemental strategy	Potentially narrower launch
Compounded or institutional alternative	Not a conventional generic substitute	Limited and fragmented impact

The largest generic barriers are likely to be product quality and manufacturing execution rather than excipient novelty. A competitor must control:

• Chelate purity and free gadolinium.
• Residual solvents and process impurities.
• Sterility and endotoxin levels.
• Particulate matter.
• Container closure integrity.
• Stability through the claimed shelf life.
• Compatibility with MRI power injectors.
• Consistent high-concentration filling.

How strong is the Gadavist patent estate?

The formulation estate appears less defensible on excipient complexity than estates for liposomal, depot or protein products. A competitor may be able to formulate a comparable product with water for injection and the same active concentration, assuming no blocking composition or method claims remain enforceable.

Patent strength should be assessed across five dimensions:

Dimension	Relative strategic assessment
Active ingredient protection	Historically important, but likely the first area examined for expiration and design-around options
Excipient protection	Appears limited because the labeled formulation is minimal
Medical-use protection	Can delay unrestricted labeling for specific indications
Process protection	May create a manufacturing barrier if API purification is specialized
Device and packaging protection	Potentially relevant to prefilled syringes and injector integration

Method-of-use patents may have practical value where a particular indication, imaging protocol or patient population has commercial importance. Their value is lower when a generic can launch with a permissible label carve-out and still compete for broad hospital demand.

What commercial opportunities exist for Gadavist excipients and delivery materials?

Can excipient suppliers replace water for injection?

Replacing water for injection is unlikely to create a strong value proposition. Water for injection is a standard, low-differentiation material. The more attractive opportunities are in quality systems, sterile water supply, packaging and manufacturing services.

Potential suppliers can compete through:

• High-volume sterile water capacity.
• Regional supply redundancy.
• Validated bulk-water systems.
• Reduced bioburden and endotoxin variability.
• Integrated filling and inspection.
• Lower-cost single-dose vial production.

Are there opportunities in container closure systems?

Yes. Container closure is the strongest excipient-adjacent opportunity.

Potential products include:

• Low-extractables rubber stoppers.
• Alternative elastomer formulations.
• Ready-to-use sterilized components.
• Low-silicone or silicone-free syringe systems.
• High-barrier polymer containers.
• Injector-compatible prefilled syringes.
• Improved particulate-control packaging.
• Closure systems designed for high-concentration gadolinium solutions.

Any alternative must demonstrate compatibility with gadobutrol, acceptable extractables and leachables, container closure integrity, sterilization compatibility, transport robustness and injector performance.

Can prefilled syringes create a meaningful commercial advantage?

Prefilled syringes can reduce dose preparation, pharmacy handling and medication errors. They may also support MRI suite throughput and standardization. The commercial case depends on whether the presentation is compatible with automated injectors and whether the total cost offsets higher packaging and device expenses.

A differentiated product could target:

• Common adult dose volumes.
• Pediatric imaging.
• High-throughput outpatient imaging centers.
• Emergency departments.
• Cardiac MRI workflows.
• Facilities seeking to reduce manual vial transfer.
• Regional markets with limited pharmacy support.

The main development risks are syringe plunger force, silicone or lubricant interactions, device connectivity, shelf-life, breakage, air management and dose delivery accuracy.

What manufacturing and intellectual-property barriers affect competition?

Gadobutrol is a macrocyclic chelate. Manufacturing requires control over chelation chemistry, purification, residual metals, related substances and free gadolinium. The active ingredient is not a simple commodity salt.

Key manufacturing barriers

1. Consistent chelation and complexation.
2. Removal of uncomplexed gadolinium.
3. Control of macrocyclic and process-related impurities.
4. High-purity water and aseptic filling.
5. Low particulate burden.
6. Reliable vial, syringe or cartridge closure.
7. Compatibility with power injectors.
8. Global supply of qualified API and packaging materials.

A supplier that can provide only a conventional excipient will have limited leverage. A supplier that combines sterile packaging, analytical testing, extractables and leachables data, and injector compatibility can address a larger portion of the development burden.

What is the FDA regulatory status of Gadavist?

Gadavist is an FDA-approved prescription injectable marketed under NDA 201277. Its regulatory profile is that of a small-molecule contrast agent rather than a biologic. The U.S. label includes multiple MRI-related uses and dosing instructions that vary by indication and patient population. [1]

The regulatory priorities for a competing product include:

• Pharmaceutical equivalence.
• Assay and impurity control.
• Sterility and endotoxin testing.
• Particulate matter.
• pH and osmolality.
• Container closure integrity.
• Stability.
• Compatibility with administration equipment.
• Appropriate labeling for approved indications.

A formulation containing a new excipient could trigger additional toxicology and clinical justification. A formulation that matches the reference product’s inactive ingredient profile generally presents a cleaner regulatory strategy, subject to FDA requirements.

What is the Orange Book and litigation status of Gadavist?

Gadavist is listed as an FDA-approved NDA product in FDA drug databases. Orange Book patent and exclusivity information must be checked against the current FDA edition and any subsequent patent-listing updates because patent status can change through delisting, expiration, litigation or settlement. [2]

No biosimilar litigation framework applies. Any Paragraph IV dispute would arise from an ANDA challenging listed patents, while a 505(b)(2) applicant could face patent certifications and use-related litigation depending on its proposed labeling and reliance on the reference product.

The most commercially important litigation questions are:

• Whether an ANDA applicant has filed a Paragraph IV certification.
• Whether Bayer has initiated a Hatch-Waxman action.
• Whether a 30-month stay has been triggered.
• Whether a settlement permits an agreed launch date.
• Whether a method-of-use patent can be carved out.
• Whether the applicant’s formulation avoids asserted claims.

How does Gadavist compare with competing gadolinium contrast agents?

Gadavist competes with products including Dotarem, ProHance, MultiHance, Eovist and other gadolinium-based contrast agents. The relevant comparison is not limited to excipients. Buyers evaluate diagnostic performance, macrocyclic versus linear chemistry, indication coverage, dosing, safety profile, supply reliability, packaging and price.

Product	Active agent	Broad formulation opportunity
Gadavist	Gadobutrol	Packaging, injector integration and supply efficiency
Dotarem	Gadoterate meglumine	Similar focus on sterile injectable manufacturing
ProHance	Gadoteridol	Potential differentiation through presentation and workflow
MultiHance	Gadobenate dimeglumine	More indication and formulation-specific competition
Eovist	Gadoxetate disodium	Liver imaging specialization limits direct substitution

Macrocyclic agents may receive preference in some institutional formularies because of their chemical stability profile, but contracting decisions also depend on indication, reimbursement, availability and total acquisition cost. [3]

What are the highest-value commercial opportunities?

The strongest opportunities are ranked below.

Opportunity	Commercial attractiveness	Main risk
Low-extractables vial and stopper system	High	Qualification and compatibility data
Prefilled syringe for MRI injectors	High	Device cost and workflow validation
Regional sterile filling and packaging	High	Capital intensity and regulatory compliance
API manufacturing or second-source supply	High	Complex chemistry and impurity control
Silicone-reduced delivery system	Medium	Plunger and injection-performance risk
New formulation excipient	Low to medium	Limited technical need and added regulatory burden
Single-dose pediatric presentation	Medium	Smaller volume and pricing pressure
Stability-enhancing excipient package	Low	Reference formulation is already simple

Key Takeaways

• Gadavist uses a minimal U.S. formulation centered on gadobutrol and water for injection.
• The product has limited apparent excipient complexity, reducing opportunities for conventional excipient substitution.
• The most attractive opportunities are container closure, prefilled syringes, injector integration, sterile filling, API supply and particulate-control systems.
• Gadavist is a small-molecule product; biosimilar pathways do not apply.
• Generic competition would likely focus on ANDA or 505(b)(2) routes, depending on formulation and presentation.
• Manufacturing control over gadobutrol purity, free gadolinium, sterility and container compatibility is likely more important than novel excipient selection.
• Current Orange Book listings, Paragraph IV filings and litigation outcomes must be evaluated against the live FDA and court records before making a launch or licensing decision.

FAQs

Is Gadavist a preservative-free contrast agent?

Yes. The U.S. product label identifies gadobutrol and water for injection and does not identify a conventional antimicrobial preservative. Gadavist is supplied as a single-dose sterile injectable product. [1]

Can a generic Gadavist use a different excipient?

Potentially, but a different excipient could increase CMC, toxicology, compatibility and regulatory requirements. A matching formulation is generally the lower-risk development strategy unless the alternative excipient solves a measurable stability or delivery problem.

Is gadobutrol protected by a biologic exclusivity period?

No. Gadobutrol is a small-molecule active ingredient. The biosimilar framework does not apply.

What packaging technology is most promising for a Gadavist competitor?

A prefilled syringe or injector-compatible container using low-extractables elastomers and controlled lubrication is the most commercially credible packaging opportunity. The product must meet injector, sterility, particulate and container-closure requirements.

Does Gadavist have a strong excipient patent moat?

The labeled formulation does not indicate a complex excipient platform. Any remaining competitive moat is more likely to involve active-ingredient claims, medical-use claims, manufacturing know-how, quality control and commercial supply execution than novel excipient protection.

References

1. U.S. Food and Drug Administration. (2024). Gadavist (gadobutrol) injection prescribing information. Bayer HealthCare Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Gadolinium-based contrast agents: Drug safety communication. FDA.